Kymera Therapeutics, Inc. (KYMR) stock
KYMRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 9/30227% above fair value
$121.13−0.39 (-0.32%)
Close on Nov 18, 2026Market cap $10.34BP/E –Yield –
Kymera Therapeutics gross margin
Gross margin is gross profit as a percentage of revenue.
Kymera Therapeutics's gross margin for the twelve months ending Sep 30, 2026 was 0.0%. For fiscal 2025 it was 0.0%, against 0.0% the year before.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0.0% | +0.0 |
| FY2024 | Dec 31, 2024 | 0.0% | +0.0 |
| FY2023 | Dec 31, 2023 | 0.0% | +0.0 |
| FY2022 | Dec 31, 2022 | 0.0% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 0.0% | +0.0 |
| Q1 FY2026 | Mar 31, 2026 | 0.0% | +0.0 |
| Q4 FY2025 | Dec 31, 2025 | 0.0% | +0.0 |
| Q3 FY2025 | Sep 30, 2025 | 0.0% | +0.0 |
| Q2 FY2025 | Jun 30, 2025 | 0.0% | +0.0 |
| Q1 FY2025 | Mar 31, 2025 | 0.0% | +0.0 |
| Q4 FY2024 | Dec 31, 2024 | 0.0% | – |
| Q3 FY2024 | Sep 30, 2024 | 0.0% | – |
| Q2 FY2024 | Jun 30, 2024 | 0.0% | – |
| Q1 FY2024 | Mar 31, 2024 | 0.0% | – |
See a number that looks wrong?